We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
10.50 | 0.78% | 1,352.00 | 1,351.00 | 1,352.00 | 1,353.00 | 1,341.00 | 1,341.00 | 1,012,497 | 10:07:28 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1889 | 11.33 | 55.61B |
Date | Subject | Author | Discuss |
---|---|---|---|
04/5/2021 15:18 | I have just found out the AGM is covered online by LUMI tomorrow. My problem is that it says I will need a SRN and a PIN to access. I have tried my broker Interactive Investor but, so far. they only say they will try to get back to me. Anyone with II know if this info is available in my account online? I can't find it. Thanks | mcflies | |
04/5/2021 14:56 | (Alliance News) - GlaxoSmithKline PLC investee ViiV Healthcare on Tuesday said US health regulators have kicked off rolling review of its Cabotegravir HIV prevention drug. The rolling submission for a new drug application allows ViiV to submit portions of data for regulatory approval from the US Food & Drug Administration. It means ViiV does not have to wait until all data is ready for submission. Cabotegravir is a HIV pre-exposure prophylaxis, or PrEP, drug. ViiV said submission of the drug will be based on results from two phase IIb/III trials. "With today's announcement we're one step closer to being able to provide the first, long-acting, therapy to prevent HIV," ViiV Head of Research & Development Kimberly Smith said. ViiV is majority-owned by GSK, with Pfizer Inc and Shionogi Ltd also owning stakes. | poikka | |
04/5/2021 14:09 | Thanks. That is the article in full. The strange thing is that, unlike other Covid hit sectors, pharma has been slow to show any share price recovery? | alex1621 | |
04/5/2021 13:10 | The key date is 23 June 2021, the capital markets day, when the projections for both new entities are placed on the table. If it's unimpressive we might see Elliot et al show their teeth. | alex1621 | |
04/5/2021 12:56 | She desperately needs to pull something out of the hat tomorrow or she will be in a very weak position. She may have done little wrong in steering the company in a new direction, but her total failure to keep analysts and stock market on side is quite unforgivable. | mcflies | |
04/5/2021 12:36 | Monty must be on half term this week! | spoole5 | |
04/5/2021 12:12 | GSK shareprice below what it was 25 years, nothing much will change, except dividends will be cut, if not for Elliott speculation I reckon 1225p on those figures the other day. | montyhedge | |
04/5/2021 07:12 | Nothing special there .... 37.67 USD +0.33 (0.88%) | tradermichael | |
04/5/2021 07:05 | NYSE. GSK .There chart above | notbitcoin | |
04/5/2021 06:56 | What listing are you looking at, please? | tradermichael | |
03/5/2021 20:21 | Up 30p in USA.Rumours could be true | notbitcoin | |
03/5/2021 17:33 | Pfizer up state side 2.7% , hopefully good omens for GSK tomorrow | whatsup32 | |
03/5/2021 15:40 | Maybe with Elliott arriving she might not progress beyond the split but cannot see her moving on before then. Wouldn’t achieve anything anyway, the die is cast pharma wise for the next couple of years | daneswooddynamo | |
03/5/2021 15:19 | If you like, but 30th June seems an awfully long way off when you're clinging to the cliff edge by your immaculately manicured finger nails....spud | spud | |
03/5/2021 14:38 | Is that a rolling quarterly forecast Spud? | daneswooddynamo | |
03/5/2021 14:02 | We had same issue at Aviva , with Tulloch. Got rid of him and let’s get rid of her. Wonder how much she’ll get paid for failure , probably in millions . | whatsup32 | |
03/5/2021 14:01 | A similar situation to the dopey bird at Imperial Brands. | meijiman | |
03/5/2021 13:54 | EW out before end Q2. spud | spud | |
03/5/2021 13:07 | Small article in the Times today. “ large shareholders have made contact with the New York hedge fund since its emergence on the shareholder register last month. It has a stake of less then 5% in the £68B co” States chiefs position in doubt and there is no desire to protect her . Update is due June 23 | whatsup32 | |
03/5/2021 09:26 | No worries. Have a nice day | whatsup32 | |
03/5/2021 08:26 | Oh my apologies WhatsUp! | markbelluk | |
03/5/2021 07:33 | Am no chartist but looks to me as though broken out of long term down channel so should be better long term hold I am holding small amount | ttg100 | |
03/5/2021 06:45 | If not for the Elliott so call share purchase, not a word from them, they can't do sweet FA with a small stake.But they are underpinning the shareprice at this high level. Because on those quarterly figures GSK should be 1225p. | montyhedge |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions